I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
0.947
-0.033 (-3.34%)
Nov 21, 2024, 1:47 PM EST - Market open
I-Mab Employees
I-Mab had 220 employees as of December 31, 2023. The number of employees decreased by 158 or -41.80% compared to the previous year.
Employees
220
Change
-158
Growth
-41.80%
Revenue / Employee
$15,064
Profits / Employee
-$374,051
Market Cap
77.14M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 220 | -158 | -41.80% |
Dec 31, 2021 | 378 | 150 | 65.79% |
Dec 31, 2020 | 228 | 43 | 23.24% |
Dec 31, 2019 | 185 | 51 | 38.06% |
Dec 31, 2018 | 134 | - | - |
Related Stocks
Company Name | Employees |
---|---|
P3 Health Partners | 400 |
MDxHealth | 300 |
OptimizeRx | 136 |
Chimerix | 72 |
Armata Pharmaceuticals | 66 |
ESSA Pharma | 50 |
Quince Therapeutics | 32 |
Clearside Biomedical | 30 |
IMAB News
- 6 hours ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 7 days ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire
- 15 days ago - I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer - PRNewsWire
- 21 days ago - I-Mab to Release Q3 2024 Financial Results on November 14, 2024 - PRNewsWire
- 22 days ago - I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 - PRNewsWire
- 24 days ago - I-Mab to Participate at the Truist Securities BioPharma Symposium - PRNewsWire
- 2 months ago - I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 - PRNewsWire
- 2 months ago - I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer - PRNewsWire